Continuation of systemic treatment in patients with cutaneous T-cell lymphoma is associated with reduced health care resource utilization

Background: Treatment for cutaneous T-cell lymphoma (CTCL) consists of skin-directed therapies for early-stage and systemic therapies (ST) for advanced disease. STs include extracorporeal photopheresis (ECP), retinoids, interferons, histone deacetylase inhibitors (HDACi), human antibodies, and chemotherapy, according to the NCCN guidelines. We conducted a database analysis to assess ST continuation.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research

Related Links:

Abstract Advanced stage mycosis fungoides (MF) and Sézary syndrome (SS) account for ~30% of patients with cutaneous T-cell lymphomas (CTCL). The prognosis is poor with a median survival of 36 months.1 Treatments rarely result in durable remissions and recent management guidelines recommend allogeneic haematopoietic stem cell transplant (HSCT) for eligible patients as the best chance of improved survival. PMID: 31536644 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
This article is protected by copyright. All rights reserved. PMID: 31278742 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
CONCLUSION: We found hypopigmented MF to be the most common clinical presentation in patients under 18 years of age. The disease did not progress to advanced stages in any of the patients, although recurrence after treatment interruption was common. PMID: 31277835 [PubMed - as supplied by publisher]
Source: Actas Dermo-Sifiliograficas - Category: Dermatology Authors: Tags: Actas Dermosifiliogr Source Type: research
We describe cutaneous SCC of the plantar foot in two patients exposed to high doses of PLD. A 50-year-old man with angiosarcoma received a total PLD dose of 1350  mg/m2 and developed cutaneous SCC of bilateral plantar feet. A 45-year-old woman with cutaneous T-cell lymphoma was treated with a total PLD dose of 1142  mg/m2 with subsequent diagnosis of cutaneous SCC of the right plantar foot. No risk factors for SCC of the plantar foot were identified in either patient. Cutaneous SCC is likely an unreported side effect of prolonged exposure to PLD. An extended duration of hand –foot syndrome from other anti-c...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Aseem K Tiwari, Dinesh Arora, Pratibha Dhiman, Sheilly Kapoor, Geet Aggarwal, Ravi C Dara, Ashok VaidAsian Journal of Transfusion Science 2019 13(1):66-69Sezary syndrome (SS) is more aggressive leukemic variant of cutaneous T-cell lymphoma in which a significant number of circulating malignant (Sezary) cells are observed in peripheral blood. Although single-agent or combination chemotherapy regimens have produced moderately high response rates in patients with advanced-stage SS, these responses are invariably not durable. Extracorporeal photopheresis (ECP) is recommended as an immunomodulator treatment, offering better lif...
Source: Asian Journal of Transfusion Science - Category: Hematology Authors: Source Type: research
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL) primarily arising in the skin. Early diagnosis is difficult as the histology overlaps with features of inflammatory skin diseases. Even when the diagnosis is established there are no prognostic markers that predict whether the disease will be aggressive or indolent. Lastly, there are no curative treatments and MF will invariably relapse even after aggressive chemotherapy. The main objective of this study is to address the presence of intratumor heterogeneity in MF.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Carcinogenesis and Cancer Genetics Source Type: research
Discussion In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment. Defects in Immune Responses That Predispose to Lymphomagenesis in PIDDs The complex immune mechanisms and their interplay that predisposes to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers (Figure 3). An underlying intrinsic susce...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Erica S. Tarabadkar† and Michi M. Shinohara*† Division of Dermatology, University of Washington, Seattle, WA, United States Skin directed therapies (SDTs) serve important roles in the treatment of early stage cutaneous T-cell lymphoma (CTCL)/mycosis fungoides (MF), as well as managing symptoms and improving quality of life of all stages. There are now numerous options for topical therapies that demonstrate high response rates, particularly in early/limited MF. Phototherapy retains an important role in treating MF, with increasing data supporting efficacy and long-term safety of both UVB and PUVA as ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, MPT0G413 and BTZ synergistically inhibit MM viability, providing a framework for the clinical evaluation of combined therapies for MM. Introduction Multiple myeloma (MM) is a B cell malignancy characterized by the proliferation of bone marrow (BM) plasma cells and the production of large amounts of abnormal immunoglobulins (1) In the United States, it was estimated that 30,770 new MM cases would be diagnosed in 2018, accounting for 1.8% of newly diagnosed cancer cases (2). Furthermore, 12,770 MM-related deaths in 2018 accounted for an estimated 2.1% of all cancer deaths (2). In the past decade, MM t...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This article is protected by copyright. All rights reserved. PMID: 30565216 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
More News: Academies | Chemotherapy | Cutaneous T cell lymphoma | Databases & Libraries | Dermatology | Health Management | Lymphoma | Skin | T-cell Lymphoma